Omeros Corp (OMER) Stock Price, Quote & News

Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has...

Industry: Biotechnology

Sector: Healthcare

Phone: 206 676 5000

Website: www.omeros.com

Address:

The Omeros Building, 201 Elliott Avenue West, Seattle, United States

Stax4mayorR Aug. 27 at 12:46 AM

$OMER Around what price u think will we be around January?

4 · Reply

Stax4mayorR Aug. 27 at 12:43 AM

$OMER real talk Omer need to rip asap

0 · Reply

LeaLeb Aug. 26 at 8:14 PM

$OMER Options volume is much higher than usual the last 2 weeks. Just hedging, who knows.

2 · Reply

MinnieSteve3 Aug. 26 at 7:18 PM

$OMER With today's trading volume, the Sept 19 $5 call option will see open interest over 10,000 options -- over 1 million shares. Also, the Sept 19 $6 call option will see open interest close to 4,000 options.

1 · Reply

LeaLeb Aug. 26 at 5:03 PM

$OMER

1 · Reply

betonthenews Aug. 26 at 3:11 PM

$OMER FWIW, my speculation: The FDA may request a detailed efficacy data analysis of pediatric subgroup in EAP, which fits GD's comments of huge amount data submitted to answer the request, my read is FDA may be intent to include the pediatric use in the label if the efficacy is convincing and GD says the data set is highly SS. And the pending partnership is waiting the label talk to confirm if pediatric use is in the label talk, which makes NARSO more valuable in the deal.

4 · Reply

Iceman89 Aug. 26 at 10:58 AM

$OMER What are the conservative price targets for this right after the approval? PT of $20-25 with the planned partnership, $10 - $15 with secondary offering?

5 · Reply

investlong871 Aug. 25 at 8:15 PM

$OMER @ipdamages at your leisure, can you help me understand the ravulizumab situation in TMA. I’m understanding the peds situation but in adults I’m less clear how to deduce what’s going on there with that trial.

1 · Reply

WinstonWolfff Aug. 25 at 5:12 PM

$OMER A quick reminder to potential Omeros partners -> If you wait too long to close a partnership deal and the FDA grants earlier approval, you will pay the maximum price and may also see a few more competing bidders. Thank you for your attention to this matter.

1 · Reply

MikeLogan Aug. 25 at 4:23 PM

$OMER Added $4.319. MMs going to let me get my average below $5 before blast off?

2 · Reply

Omeros Corporation (OMER) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 4:02 PM EDT - 12 days ago

Omeros Corporation Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 4:02 PM EDT - 15 days ago

Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025

Jul 25, 2025, 8:00 AM EDT - 4 weeks ago

Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering

Jun 27, 2025, 8:30 AM EDT - 2 months ago

Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA

Jun 24, 2025, 8:30 AM EDT - 2 months ago

Omeros Announces Webcast Details for Annual Meeting of Shareholders

Jun 10, 2025, 12:53 PM EDT - 2 months ago

Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision

May 27, 2025, 11:12 PM EDT - 3 months ago

Omeros: On The Brink As It Awaits Its Fall PDUFA For A Potential Blockbuster

May 27, 2025, 7:20 AM EDT - 3 months ago

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter

AGL ANIP

May 15, 2025, 9:07 PM EDT - 3 months ago

Omeros Corporation (OMER) Q1 2025 Earnings Conference Call Transcript

May 15, 2025, 4:05 PM EDT - 3 months ago

Omeros Corporation Reports First Quarter 2025 Financial Results

May 12, 2025, 5:05 PM EDT - 3 months ago

Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025

May 12, 2025, 10:35 AM EDT - 3 months ago

Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026

May 6, 2025, 9:16 AM EDT - 4 months ago

FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date

Apr 11, 2025, 3:06 PM EDT - 4 months ago

Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight

Apr 10, 2025, 9:10 AM EDT - 4 months ago

Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' Proprietary OncotoX-AML Clinical Program

Apr 8, 2025, 9:00 AM EDT - 5 months ago

Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases

Mar 31, 2025, 8:57 PM EDT - 5 months ago

Omeros Corporation (OMER) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 4:02 PM EDT - 5 months ago

Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results

Mar 28, 2025, 7:39 AM EDT - 5 months ago

Top Wall Street Forecasters Revamp Omeros Price Expectations Ahead Of Q4 Earnings

Mar 26, 2025, 9:15 AM EDT - 5 months ago

Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025

Mar 21, 2025, 9:15 AM EDT - 5 months ago

Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program

Feb 24, 2025, 4:44 PM EST - 6 months ago

Omeros Corporation: Scientifically Compelling Again, But The Delay Has Cost Us

Feb 20, 2025, 9:10 AM EST - 6 months ago

Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA

Feb 14, 2025, 9:00 AM EST - 6 months ago

Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings

Feb 10, 2025, 9:00 AM EST - 7 months ago

Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program

Jan 16, 2025, 9:15 AM EST - 7 months ago

Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint

Dec 19, 2024, 12:28 PM EST - 8 months ago

Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges

Dec 19, 2024, 9:15 AM EST - 8 months ago

Omeros' Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA

Dec 10, 2024, 8:45 AM EST - 9 months ago

Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting

Dec 2, 2024, 8:45 AM EST - 9 months ago

Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting

Nov 21, 2024, 9:15 AM EST - 9 months ago

Omeros Corporation Provides Update on Progress Toward BLA Resubmission

Nov 13, 2024, 10:22 PM EST - 10 months ago

Omeros Corporation (OMER) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 4:02 PM EST - 10 months ago

Omeros Corporation Reports Third Quarter 2024 Financial Results

Nov 11, 2024, 4:11 PM EST - 10 months ago

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024

Oct 24, 2024, 8:45 AM EDT - 10 months ago

FDA Grants Rare Pediatric Disease Designation to Omeros' MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy

Aug 10, 2024, 1:05 AM EDT - 1 year ago

Omeros Corporation (OMER) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:02 PM EDT - 1 year ago

Omeros Corporation Reports Second Quarter 2024 Financial Results

Aug 5, 2024, 4:02 PM EDT - 1 year ago

Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024

Jun 3, 2024, 9:00 AM EDT - 1 year ago

Omeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028

May 15, 2024, 7:23 PM EDT - 1 year ago

Omeros Corporation (OMER) Q1 2024 Earnings Call Transcript

May 15, 2024, 4:02 PM EDT - 1 year ago

Omeros Corporation Reports First Quarter 2024 Financial Results

May 10, 2024, 8:50 AM EDT - 1 year ago

Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024

May 9, 2024, 8:50 AM EDT - 1 year ago

Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress

Apr 1, 2024, 8:09 PM EDT - 1 year ago

Omeros Corporation (OMER) Q4 2023 Earnings Call Transcript

Apr 1, 2024, 4:02 PM EDT - 1 year ago

Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results

Mar 27, 2024, 8:30 AM EDT - 1 year ago

Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024

Feb 20, 2024, 9:00 AM EST - 1 year ago

Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy

Feb 1, 2024, 9:11 AM EST - 1 year ago

Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust

Nov 27, 2023, 1:18 AM EST - 1 year ago

Omeros: Why It Is Worthwhile To Bet On Narsoplimab

Stax4mayorR Aug. 27 at 12:46 AM

$OMER Around what price u think will we be around January?

4 · Reply

Stax4mayorR Aug. 27 at 12:43 AM

$OMER real talk Omer need to rip asap

0 · Reply

LeaLeb Aug. 26 at 8:14 PM

$OMER Options volume is much higher than usual the last 2 weeks. Just hedging, who knows.

2 · Reply

MinnieSteve3 Aug. 26 at 7:18 PM

1 · Reply

LeaLeb Aug. 26 at 5:03 PM

$OMER

1 · Reply

betonthenews Aug. 26 at 3:11 PM

4 · Reply

Iceman89 Aug. 26 at 10:58 AM

$OMER What are the conservative price targets for this right after the approval? PT of $20-25 with the planned partnership, $10 - $15 with secondary offering?

5 · Reply

investlong871 Aug. 25 at 8:15 PM

1 · Reply

WinstonWolfff Aug. 25 at 5:12 PM

1 · Reply

MikeLogan Aug. 25 at 4:23 PM

$OMER Added $4.319. MMs going to let me get my average below $5 before blast off?

2 · Reply

MinnieSteve3 Aug. 25 at 3:27 PM

$OMER The last trade I saw on my Schwab account for OMER was $4.36861. Come on, MM's.

0 · Reply

MinnieSteve3 Aug. 25 at 3:01 PM

$OMER Still a lot of interest in the Sept 19 $5 call options. Last friday 1,178 options were traded making the open interest 9,198 options. (Note: 1 option = 100 shares.)

0 · Reply

Iceman89 Aug. 25 at 2:49 PM

$OMER https://investor.omeros.com/news-releases/news-release-details/omeros-announces-robust-results-narsoplimab-expanded-access

0 · Reply

capntrps Aug. 25 at 2:43 PM

$OMER i could use a break out here. Ready any time, disapointed ne on Friday. Who knows...

0 · Reply

seanleecfa Aug. 25 at 2:20 PM

$OMER look at $HCWB today - another low float biotech with big news up 100+%. We may have more than one of these days occur by the end of the year.

0 · Reply

Iceman89 Aug. 25 at 2:06 PM

$OMER research paper with data coming out soon according to latest CC

0 · Reply

izacmann Aug. 25 at 1:03 PM

$OMER this could be a nice week!

1 · Reply

betonthenews Aug. 22 at 5:06 PM

$OMER Check out Q2 institution holdings, most interesting is who bought more OMER in Q2: https://www.nasdaq.com/market-activity/stocks/omer/institutional-holdings?page=1&rows_per_page=10

5 · Reply

WinstonWolfff Aug. 22 at 4:42 PM

$OMER Expecting a quick run up into the close. There is always a crowd buying 50-100k shares on Friday for possible Monday news.

3 · Reply

gordonator Aug. 22 at 4:19 PM

$OMER couldn’t resist

1 · Reply

Stocksfirst Aug. 22 at 3:57 PM

$OMER - who would like their investment dollars that are sitting here in either Ethereum or Bitcoin???…………ME!!!!!!!

3 · Reply

AgentMulder Aug. 22 at 3:26 PM

$OMER Damn every stock BUT OMER up in my portfolio….suck-le-blue!!! Cmon man….

3 · Reply

Market Cap	296.04M
Revenue (ttm)	0.00
Net Income (ttm)	-156.82M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-0.73

Volume	892,700
Avg Vol	1,236,534
Day's Range	N/A - N/A
Shares Out	68.06M
Stochastic %K	63%
Beta	2.26
Analysts	Sell
Price Target	$22.50